Consumer AI dermatologist apps scan photos of a stubborn rash or eczema and return automated risk indications or look-alike matches under disclaimers that they do not diagnose skin disease. On FutureClinic, a specific human doctor reads your whole case and answers you with a live-recorded video or voice note called a Human Signature, and no form is approved in bulk.

We believe that AI is a tool for doctors and that the doctor is in charge of every case. Only an expert can tell when an AI has made a mistake or is heading toward the wrong answer. On FutureClinic, the AI works behind the scenes like a chief resident: it gathers your history and photos so the doctor moves faster, and it never gives medical advice by itself. Every doctor is a physician with an MD, DO or MBBS degree, never a nurse practitioner or physician assistant.

How do AI dermatologist apps compare with messaging a doctor?

Search results for an AI dermatologist mix screening apps, photo consults, AI bots, and physician clinics (prices as of October 2026).

On FutureClinic, a real doctor reads every case and decides, you keep the same doctor, and no subscription is required. Doctronic gives free AI answers in seconds, ScanSkinAI offers a first check free and $4.99 single checks as of October 2026, and First Derm starts at $34.95 as of October 2026. Real care from a doctor takes hours: FutureClinic replies typically come within a few hours, almost always the same day or the next.

That contrast points to a practical question: do you want a standalone software scan with its medical disclaimers, or did you want a doctor of your own who can evaluate your skin and prescribe treatment by message?

What do consumer AI skin apps say, and what has the FDA cleared?

In the US, consumer skin apps disclaim diagnosis. SkinVision is CE-marked in Europe, but its US page states "SkinVision is not yet available in the United States" and "U.S. availability is subject to FDA authorization" (announcing an FDA trial with Mayo Clinic in March 2026). Skinive is CE-marked in the UK, while its US listing (August 2026) says "Skinive does not identify, diagnose, or treat acne, eczema, rashes", and AI Dermatologist: Skin Scanner states on Google Play (October 2026) that "It is not a diagnostic tool and not a medical device". ScanSkinAI claims "Up to 96.48% Accuracy" and sells clinician commentary ($19.99 to $39.99 as of October 2026), yet its March 2026 terms state this "does NOT establish a doctor-patient relationship", while Google ended its DermAssist tool ("no longer in development").

The American Academy of Dermatology (AAD) notes that "None of these apps has been approved by the U.S. Food and Drug Administration". Under the FDA's January 6, 2026 General Wellness policy, software avoids device rules only when unrelated to diagnosing or treating disease. The FDA's AI-Enabled Medical Devices list (September 4, 2026) names three skin-lesion devices: MelaFind (2011), Nevisense (2017), and DermaSensor (cleared January 12, 2024). All three are prescription instruments for physicians; in its 1,005-patient pivotal study, DermaSensor had 95.5% sensitivity and 20.7% specificity.

What do studies show about accuracy, phone photos, and darker skin?

In a 340-case Chilean study (Muñoz-López et al., 2021), an AI was right first time in 41.2% of cases versus 60.1% for dermatologists.

In 21 open datasets, only 2.1% of 106,950 images recorded skin type (Wen et al., 2022). On Stanford's 656-image dataset (Daneshjou et al., 2022), sensitivity on light (types I to II) versus dark skin (types V to VI) fell from 0.69 to 0.23 for DeepDerm and 0.41 to 0.12 for ModelDerm. In Uganda (Kamulegeya et al., 2023), First Derm's AI search ($11.99 per use as of October 2026) hit 17% accuracy on type VI skin, against 69.9% reported on white skin in its training. Testing ChatGPT 5.2 Edu and Gemini 3.1 Pro, Bhagwat et al. (August 2026) concluded "Neither configuration supports autonomous dermatologic use".